drugset / Trial / NCT04857164
Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in China
NaSingle-groupOpen-labelTreatment
Summary
This trial is main evaluate the efficacy and safety of pembrolizumab combined with chemotherapy in the first-line treatment of Chinese patients with recurrent or metastatic head and neck squamous cell carcinoma
Timeline
- Start
- 2021-04-30
- Primary completion
- 2023-08-20
- Completion
- 2026-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 5 unknown | — |
| Subject | Cisplatin | Other / unclassified | 25 mg/m2 | — |
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | — |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Background | Paclitaxel | Small molecule | 260 mg/m2 | — |